Genocea Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Clark
- Full Time Employees
- 74
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Acorn Park Dr Cambridge MA United States of America 02140
- IPO Date
- Feb 5, 2014
- CIK
- 0001457612
- Website
- genocea.com
- Similar Companies
- Business
- Genocea Biosciences, Inc. (GNCAQ) operates as a biopharmaceutical company that discovers and develops novel cancer immunotherapies using its proprietary ATLAS platform, which profiles patient CD4+ and CD8+ T cell responses to tumor antigens identified via next-generation sequencing; key products include GEN-011, an adoptive T cell therapy in Phase 1/2a trials for solid tumors, and GEN-009, a neoantigen vaccine delivering adjuvanted synthetic long peptides targeting ATLAS-identified anti-tumor neoantigens. The company, founded in 2006 and headquartered at 100 Acorn Park Drive in Cambridge, Massachusetts, previously pursued infectious disease vaccines like GEN-003 for genital herpes before pivoting to immuno-oncology in 2017 with significant staff reductions. In recent major developments, Genocea filed for voluntary Chapter 11 bankruptcy reorganization on July 5, 2022, following disappointing Phase 1/2a results for GEN-011, announced plans to wind down operations and delist from Nasdaq in May 2022 with 65% workforce cuts, and received court approval for a joint liquidation plan on May 11, 2023, canceling equity interests without distribution while funding payouts from cash and asset sales to priority claimants.
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN)
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Genocea to Present at Upcoming Investor Conferences
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast
Genocea to Present at Upcoming Conferences
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
Genocea to Present at Upcoming Scientific and Investor Conferences
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
Genocea Biosciences, Inc. (GNCA) CEO Chip Clark on Q2 2021 Results - Earnings Call Transcript
Genocea Provides Second Quarter 2021 Corporate Update
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast